Salute e Benessere

Israel Honors Pfizer CEO Albert Bourla with the "Jewish Nobel" Prize

The gala event brought together hundreds of dignitaries from Israel, including government ministers, heads of business and philanthropic organizations, as well as prominent representatives of the Jewish Diaspora and leading members of the global medical community. The gala event brought together hundreds of dignitaries from Israel, including government ministers, heads of business and philanthropic organizations, as well as prominent representatives of the Jewish Diaspora and leading members…

Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide…

105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses NEW YORK and MAINZ, GERMANY, JUNE 29, 2022— Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new vaccine supply agreement with the U.S. government to support the continued fight against COVID-19. Under the agreement, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg). This may...

The International Consortium for Health Outcomes Measurement (ICHOM) will hold…

There will be plenty of networking opportunities including an ICHOM welcome drinks reception, networking breakfasts and interactive conference sessions. There will be plenty of networking opportunities including an ICHOM welcome drinks reception, networking breakfasts and interactive conference sessions. Key topics include: To find out more about the agenda – visitconference.ichom.org/agenda Confirmed speakers include: To view the confirmed speakers, visithttps://conference...

Eurofins DiscoverX Celebrates Shanghai Office Opening

With this fully operational Shanghai office, Eurofins DiscoverX can more readily provide its product menu cell lines, assay reagents, enzymes and bioassay kits to the China market. The new Shanghai operation provides an efficient supply chain, local technical support, and the convenience for clients to pay in the Chinese Yuan (RMB) currency. With this fully operationalShanghaioffice, Eurofins DiscoverX can more readily provide its product menu cell lines, assay reagents, enzymes and...

Freya Pharma Solutions Announced Its Application for EMA Scientific Advice on…

"This application for EMA scientific advice is a major step in Freya's development program for Lybrido, which is offering an effective and safe treatment for women suffering from FSIAD. Lybrido will be an innovative drug in a market with very few approved drugs in the United States, and no drug being approved in Europe so far." "This application for EMA scientific advice is a major step in Freya's development program for Lybrido, which is offering an effective and safe treatment…

Dermatology Devices Market worth $11.3 billion by 2027 - Exclusive Report by…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=154 The growth in this market is expected to be driven by the rising incidence of skin disorders, increasing awareness of aesthetic procedures, and technological advancements. However, the stringent regulatory policies for medical devices may hinder the growth of this market. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=154 The growth in this market is expected to be driven by...

The Global Vascular Stents Market to Surge at a CAGR of 7.90% by 2027 |…

Key Takeaways from the Vascular Stents Market Key Takeaways from the Vascular Stents Market To read more about the latest highlights related to vascular stents, get a snapshot of the key highlights entailed in the Vascular Stents Market Report Vascular Stents Vascular stents are small tubular scaffolds generally used in the treatment of arterial stenosis to prevent acute vessel closure and late restenosis in a variety of vessels such as coronary arteries. The procedure in...

Value of Cervical Cancer Diagnostic Tests Market estimated at US$ 13.6 Bn by…

High incidence of human papillomavirus infection in women population and long-term use of oral contraceptives that are related to cervical cancer underscores demand for cervical cancer diagnostic tests. High incidence of human papillomavirus infection in women population and long-term use of oral contraceptives that are related to cervical cancer underscores demand for cervical cancer diagnostic tests. Role of large pharmaceutical companies toward discovering improved treatment for cervical...

Hemcheck receives extended order from its French distributor

For further information contact: For further information contact: Hemcheck Sweden AB (publ) Joen Averstad, CEO Tel: +46 76 108 8191 Email:[email protected] About Hemcheck Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas...

New biomarkers unlock potential for more effective treatment of deadly cancers

The study investigated chromosomal instability – a distinctive feature of aggressive human cancers. Under normal conditions, a healthy cell will perfectly duplicate and divide, to form two identical daughter cells. Each daughter cell will contain the same number of chromosomes as their parent cell, with the exact same DNA sequence. In cancer cells, however, this duplication does not occur perfectly. The study investigated chromosomal instability – a distinctive feature of aggressive human…

Maxima Grupė base prospectus published and BB+ credit rating confirmed by…

In addition, on 29 June, 2022, the international credit rating agency Standard & Poor's reviewed Maxima Grupė's operations and financial performance and confirmed Maxima Grupė's a BB+ credit rating with stable outlook.Contact person:Povilas Šulys, Chief Financial Officer at MAXIMA GRUPĖ, UAB [email protected]

Resolutions passed at the Annual General Meeting

Orphazyme A/S Company announcementNo. 33/2022 www.orphazyme.com Company Registration No. 32266355 Copenhagen, Denmark, June 29, 2022– Orphazyme A/S (ORPHA.CO) (the “Company”), today held its Annual General Meeting, at which the Annual General Meeting: Financial year 2021 and 2022Took note of the Board of Directors' report on the Company's activities in the past financial year;Adopted the Company's...

Cryotherapy Market size worth $ 554.9 Million, Globally, by 2030 at 9% CAGR…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample/?rid=4803 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample/?rid=4803 Browse in-depth TOCon" Cryotherapy Market " 202 - Pages 126 – Tables 37 – Figures Global Cryotherapy Market Overview The technological advancements in cryotherapy equipment are driving the worldwide Cryotherapy Market. Cryotherapy has become a vital treatment option, owing to advancements in...

Personal Protective Equipment Kit Market size worth $ 98.72 Billion, Globally…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample/?rid=39481 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample/?rid=39481 Browse in-depth TOCon" Personal Protective Equipment Kit Market " 202 - Pages 126 – Tables 37 – Figures Global Personal Protective Equipment Kit Market Overview Having access to the personal protective equipment (PPE) needed to stay safe is critical; it reduces the risk of infection...

Insurance providers can assess customer health risks in real-time using…

The NuraLogix technology was available for demonstration at the America's Health Insurance Plans (AHIP) show in Las Vegas, Nevada from June 21 to 23. TheNuraLogixtechnology was available for demonstration at the America's Health Insurance Plans (AHIP) show inLas Vegas, NevadafromJune 21 to 23. The benefits of integrating a vital sign monitoring system into the insurance evaluation process are numerous: reduced costs of underwriting a policy, no nurses needed to conduct physical...

Personalized Nutrition Market Estimated to Surpass $37,286.9 Million and Grow at…

According to the report, the global personalized nutrition market is estimated to garner a revenue of $37,286.9 million by 2030, growing at a stable CAGR of 11.48% during the forecast period 2022-2030. According to the report, the global personalized nutrition market is estimated to garner arevenue of$37,286.9 millionby 2030, growing at astable CAGR of 11.48%during the forecast period2022-2030. Dynamics of the Personalized Nutrition Market Drivers:Rising strategic...

Cardiac Monitoring & Cardiac Rhythm Management Devices Market Worth USD 30…

The global cardiac monitoring & cardiac rhythm management devices market has been analyzed from four different perspectives – Devices for Cardiac Monitoring, Devices for Cardiac Rhythm Management, End User, and Region. The global cardiac monitoring & cardiac rhythm management devices market has been analyzed from four different perspectives – Devices for Cardiac Monitoring, Devices for Cardiac Rhythm Management, End User, and Region. Market Driver According to a paper published in...

Kedrion Biopharma Recognized for Innovation in Treating Rare Disease

The award was presented Sunday at NORD's Rare Impact Awards at the Rock & Roll Hall of Fame in Cleveland, Ohio. Rebecca Bialas, President of the Plasminogen Deficiency Foundation, presented the award to Giorgio Masetti-Zannini, VP, US Regional Commercial Director of Kedrion Biopharma, who accepted the award on behalf of Kedrion Biopharma. "We thank NORD for this honor and for all the important work they do to support those who suffer from rare diseases and conditions, said…

Signant Health Introduces Enhancements to Flagship eCOA Software

SmartSignals eCOA leverages a drag-and-drop design tool that outputs consumer-grade user interfaces that adapt automatically for any device, accelerating the study design process by 40% - 60%. It also streamlines the verification process, enabling study teams to easily visualize their eCOA study design and validate alignment with a protocol's schedule of events or activities tables. SmartSignals eCOA leverages a drag-and-drop design tool that outputs consumer-grade user interfaces that adapt...

Dialysis Equipment Market Will Reach USD 1459 Million By 2028 With A CAGR of…

Major Factors Driving The Growth of The Dialysis Equipment Market are Major Factors Driving The Growth of The Dialysis Equipment Market are The dialysis equipment market is expanding as a result of rising demand from hospitals, clinics, and dialysis facilities throughout the world. The main risk factor for kidney-related illnesses is the aging population. The increase in patients with end-stage renal disease (ESRD), rising demand for peritoneal dialysis, the development of more precise...

R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in…

Grand View Research continued: "The CNS therapeutics market has experienced extensive R&D efforts in the past decade, which have resulted in the introduction of novel drug-delivery systems. The advancements in the drug-delivery systems are expected to increase the adoption of a novel therapy to treat central nervous system diseases. These novel drug-delivery systems have an edge over conventional methods owing to reduced adverse effects. The demand for a novel drug-delivery system is…

Novozymes' financial calendar 2023

Read the full announcement in PDF Attachment 2022_24_Financial_calendar_2023

BioLineRx Enters Co-Development Agreement with GenFleet to Further Develop…

"This collaboration is based on the highly encouraging results from our Phase 2a COMBAT/KEYNOTE-202 study of Motixafortide in combination with an anti-PD-1 and chemotherapy, which provide strong support for continued development in this very challenging disease. With its broad solid tumor oncology pipeline and highly experienced development team, we believe we have found an outstanding partner in GenFleet to execute a rigorously designed randomized Phase 2b trial," said Philip Serlin…

Amolyt Pharma Strengthens Leadership Team with Appointment of Mark Sumeray…

Industry veteran brings over two decades of global experience in pharmaceutical, medical devices and biotech industries “We are very pleased to have Mark join our team,” said Thierry Abribat, Ph.D., founder, and chief executive officer of Amolyt Pharma. “We believe his experience in clinical development, particularly with endocrine and other rare diseases, will be essential as we continue to advance our lead program AZP-3601 through clinical development for hypoparathyroidism and actively...

1 (current)
2
3
4
5
6
7
8
9
10
»